Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|January 12, 2002
Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regenerationXavier Aldeguer, Fotini Debonera, Abraham Shaked, et al.Molecular Pharmacology|March 27, 2004
Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in ratsXinkang Wang, Giora Z Feuerstein, Lin Xu, et al.Atherosclerosis|March 11, 2015
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndromeJuan Gaztanaga, Michael Farkouh, James H F Rudd, et al.Journal of Hepatology|March 27, 2026
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trialJörn M Schattenberg, Pierre Bedossa, Cynthia D Guy, et al.Circulation. Cardiovascular Imaging|March 2, 2010
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndromeJean-Claude Tardif, Philippe L L'allier, Reda Ibrahim, et al.Diabetes|June 29, 2006
A glucose sensor role for glucokinase in anterior pituitary cellsDorothy Zelent, Maria L Golson, Brigitte Koeberlein, et al.Lancet (London, England)|November 16, 2019
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mustafa R Bashir, Cynthia D Guy, et al.Alimentary Pharmacology & Therapeutics|October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitisStephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.Diabetes|May 30, 2006
From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulationJørn V Sagen, Stella Odili, Lise Bjørkhaug, et al.Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Potent, selective MCH-1 receptor antagonistsShawn D Erickson, Bruce Banner, Steven Berthel, et al.Pageof 5